Cortechs.ai Unveils Next-Generation NeuroQuant® for Advanced Brain Tumor Imaging

Cortechs.ai, a leader in artificial intelligence-based medical imaging solutions, has just launched a groundbreaking update to its NeuroQuant® Brain Tumor software. This latest version, now FDA-cleared, brings fully automated segmentation and comprehensive volumetric reporting capabilities to the analysis of brain metastases and meningiomas. With this innovation, the company aims to revolutionize how clinicians approach brain tumor diagnostics and treatment monitoring.

NeuroQuant® Brain Tumor is more than just a software upgrade; it is a fully automated post-processing medical device designed to assist radiologists and neuro-oncologists alike. Its primary goal is to complement existing standards of care by providing objective segmentations and volumetric reports that enhance clinical efficiency while improving patient outcomes. With this software, clinicians can expect a transformation in the way they interpret neurological MR images, thanks to sophisticated AI algorithms that automatically segment and quantify brain tumors confirmed by pathological diagnosis.

The new release complements the existing capabilities focused on high- and low-grade gliomas, expanding the usage to include brain metastases and meningiomas. This enhanced functionality is accessible through Cortechs.ai's secure cloud environment, ensuring seamless adoption via PACS integration. As a result, hospitals and enterprise users can scale access to this innovative tool effectively and efficiently.

One of the standout features of this release is its ability to track tumor changes over time, enabling practitioners to gain essential insights into treatment responses and disease progression. This capability directly supports improved patient outcomes, which is a primary concern for healthcare professionals working in this challenging field. With this launch, real-time integration of segmentation results into radiation oncology and neurosurgical workflows has become a reality—allowing for the direct importation of segmentation files into treatment planning systems and significantly reducing the need for manual contouring.

The complexities involved in brain tumor imaging necessitate a robust solution, and clinical experts are already recognizing the substantial potential of NeuroQuant® Brain Tumor. Dr. Nikdokht Farid, a neuroradiologist at UC San Diego, states, “NeuroQuant® Brain Tumor's longitudinal tracking capabilities offer critical insights into changes in tumor volume over time, facilitating more accurate monitoring of treatment responses and more informed clinical decision-making.” He emphasizes the tool's capacity to improve workflow efficiency and clinical confidence in detecting and measuring brain tumors.

Kyle Frye, CEO of Cortechs.ai, emphasized that this technology is a game-changer for healthcare providers. “We’re enabling healthcare professionals to address complex diagnostic challenges through advanced capabilities. This software isn't merely an additional tool—it's a revolutionary innovation that bridges radiology, surgery, and oncology into a cohesive continuum of care.”

The CTO of Cortechs.ai, Nate White, echoed these sentiments by highlighting the extensive labor hours saved through this automated analysis. “This isn't just about efficiency; it’s about furnishing clinicians with the necessary tools and insights to improve patient care while streamlining workflows within strained healthcare systems.”

The NeuroQuant® Brain Tumor solution is the first FDA-cleared, cloud-native system to offer automated volumetric segmentation for both brain metastases and meningiomas, paving the way for a unified platform in neuroimaging. It builds upon Cortechs.ai's established reputation for glioma tracking and offers unprecedented accessibility to clinicians, ensuring efficient evaluation of treatment responses and high-quality care.

In conclusion, Cortechs.ai stands at the forefront of AI applications in radiology, developing technologies that not only enhance disease detection and screening but also significantly improve outcomes for patients afflicted with neurological disorders. To learn more about Cortechs.ai and its innovative solutions, visit Cortechs.ai and follow their journey on social media platforms.

Contact information: +1 858 459 9700 or [email protected]